[Sex-Based Differences and Shared Decision-Making in Myasthenia Gravis].

Abstract

Myasthenia gravis is an autoimmune disease of the neuromuscular junctions. Studies have shown that its prevalence is slightly higher in females, that female patients are more refractory to treatment, and that their post-treatment quality of life is more difficult to improve. Recently, multiple novel treatment options have become available, and more opportunities for shared decision-making are being observed in the process of treatment selection. Thus, it is necessary to choose the best treatment for each patient through detailed explanations regarding the disease and adequate consideration of sex-based differences.